Oxford BioMedica PLC Announces Agreement With Sigma-Aldrich Corporation

LONDON (AFX) - Oxford Biomedica PLC said it has licensed its Lentivector technology to Sigma-Aldrich Corp for the reagent and research tool market. This strategic alliance identifies Sigma-Aldrich as Oxford BioMedica's exclusive global partner in the development and marketing of research products based on the LentiVector technology, the company said. Under the agreement, which gives Sigma-Aldrich the exclusive right to sublicense the technology for research purposes, Oxford BioMedica will receive an upfront payment, annual minimum payments and royalties on sales.

Back to news